混合闭环胰岛素治疗与2-20岁1型糖尿病年轻人严重低血糖和糖尿病酮症酸中毒风险:一项基于人群的研究
这项基于人群的队列研究纳入德国、奥地利、瑞士和卢森堡250个糖尿病中心的13922例2-20岁1型糖尿病年轻人,比较混合闭环与传感器增强开环泵治疗。闭环组酮症酸中毒发生率更高(1.74 vs 0.96/100患者年,IRR 1.81),严重低血糖无显著差异,但低血糖昏迷发生率更低、HbA1c更低、目标范围内时间更高。
要点
- 闭环组酮症酸中毒发生率高于开环组(1.74 vs 0.96/100患者年,IRR 1.81,p<0.0001)。
- 两组严重低血糖发生率无显著差异(5.59 vs 6.63/100患者年,IRR 0.84,p=0.089)。
- 闭环组HbA1c更低、目标范围内时间更高,但HbA1c≥8.5%者酮症酸中毒风险尤其高。
核心结论
- 混合闭环胰岛素治疗对严重低血糖发生率无显著影响,与糖尿病酮症酸中毒风险增加相关,但与低血糖昏迷风险降低和血糖改善相关。
- 这些发现表明需要针对闭环胰岛素治疗的使用增加额外的教育措施。
研究设计与样本
- 这项基于人群的队列研究评估了来自德国、奥地利、瑞士和卢森堡250个糖尿病中心参与糖尿病前瞻性随访(DPV)计划的2-20岁1型糖尿病患者。
- 纳入者糖尿病病程超过1年,治疗时间为2021年1月1日至2023年12月31日。
- 主要结局为闭环治疗与开环治疗使用者的严重低血糖和酮症酸中毒发生率。
- 采用倾向评分逆概率治疗加权考虑多个基线特征以控制相关混杂因素。
主要发现
- 13922例年轻人纳入分析(中位年龄13.2岁[IQR 10.0-16.0],51%男性),其中7088例使用闭环治疗,6834例使用开环治疗,中位观察时间1.6年[IQR 1.1-2.4]。
- 闭环组酮症酸中毒发生率高于开环组(1.74 vs 0.96/100患者年;发生率比1.81[1.37-2.40],p<0.0001)。
- 两组严重低血糖发生率无显著差异(5.59 vs 6.63/100患者年;发生率比0.84[95%CI 0.69-1.03],p=0.089)。
- 闭环组低血糖昏迷发生率低于开环组(0.62 vs 0.91/100患者年;发生率比0.68[95%CI 0.48-0.97],p=0.034)。
- 闭环组HbA1c更低(7.34% vs 7.50%;差值-0.16%[95%CI -0.20至-0.13],p=0.0007),目标血糖范围3.9-10.0 mmol/L内时间百分比更高(64% vs 52%,差值12%[10-14],p<0.0001),血糖变异性更低(变异系数35.4% vs 38.3%;差值-2.9%[-3.3至-2.5],p<0.0001)。
临床怎么用
- 原文结论指出这些发现表明需要针对闭环胰岛素治疗的使用增加额外的教育措施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of closed-loop insulin delivery on the risk of acute diabetes complications in people with type 1 diabetes is unclear. We investigated whether the rates of severe hypoglycaemia and diabetic ketoacidosis are lower with hybrid closed-loop insulin therapy compared with sensor-augmented (open-loop) pump therapy in a large cohort of young people. METHODS: In this population-based cohort study, we evaluated young people with type 1 diabetes from 250 diabetes centres in Germany, Austria, Switzerland, and Luxembourg participating in the Diabetes Prospective Follow-up (DPV) initiative. Included participants were aged 2-20 years, with diabetes duration of more than 1 year, and were treated between Jan 1, 2021, and Dec 31, 2023. The primary outcomes were the rates of severe hypoglycaemia and ketoacidosis in people using closed-loop therapy versus open-loop therapy. Key secondary outcomes were differences in HbA1c levels, percentage of time in glucose range of 3·9-10·0 mmol/L, and glycaemic variability. To account for relevant confounders, we applied propensity score inverse probability of treatment weighting considering several baseline characteristics. FINDINGS: 13 922 young people (median age 13·2 years [IQR 10·0 to 16·0]; 51% male) in the DPV database met inclusion criteria and were included in the analysis. 7088 used closed-loop therapy and 6834 used open-loop therapy, with a median observation time of 1·6 years [IQR 1·1 to 2·4]. Individuals using closed-loop therapy had a higher rate of ketoacidosis (1·74 per 100 patient-years) than those using open-loop therapy (0·96 per 100 patient-years; incidence rate ratio 1·81 [1·37 to 2·40], p<0·0001) and there was no significant difference between groups in the rate of severe hypoglycaemia (5·59 per 100 patient-years vs 6·63 per 100 patient-years; incidence rate ratio 0·84 [95% CI 0·69 to 1·03], p=0·089). Individuals using closed-loop therapy had a lower rate of hypoglycaemic coma (0·62 per 100 patient-years) compared with individuals using open-loop therapy (0·91 per 100 patient-years; incidence rate ratio 0·68 [95% CI 0·48 to 0·97], p=0·034). Those in the closed-loop therapy group also had a lower HbA1c level (7·34% vs 7·50%; difference -0·16% [95% CI -0·20 to -0·13], p=0·0007), higher percentage of time in target glucose range of 3·9-10·0 mmol/L (64% vs 52%, difference 12% [10 to 14], p<0·0001), and less glycaemic variability (coefficient of variation 35·4% vs 38·3%; difference -2·9% [-3·3 to -2·5], p<0·0001) than those in the open-loop therapy group. The rate of ketoacidosis was particularly high in young people with HbA1c of 8·5% or higher in the closed-loop therapy group (5·25 per 100 patient-years) compared with the open-loop therapy group (1·53 per 100 patient-years; incidence rate ratio 3·43 [95% CI 1·69 to 6·97], p<0·0001). INTERPRETATION: Hybrid closed-loop insulin delivery has no significant effect on the rate of severe hypoglycaemia, and is associated with an increased risk of diabetic ketoacidosis, but is associated with a reduced risk of hypoglycaemic coma and improved glycaemia. These findings indicate the need for additional educational measures for the use of closed-loop insulin delivery. FUNDING: German Center for Diabetes Research, German Diabetes Society, and Robert Koch Institute.
引用
- Karges B, Rosenbauer J, Stahl-Pehe A, et al. Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2-20 years) with type 1 diabetes: a population-based study. Lancet Diabetes Endocrinol. 2024. PMID: 39701114. doi:10.1016/S2213-8587(24)00284-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。